

MAIL VOTING FORM

The shareholder stated below hereby cast votes in accordance with Schedule 1 at the annual general meeting in InDex Pharmaceuticals Holding AB, reg. no. 559067-6820, on 1 June 2022.

Shareholder

Name of the shareholder:		Personal identification number or corporate registration number:
Number of shares in InDex Pharmaceuticals Holding AB:		Daytime telephone number:
Date:	Signature:	Clarification of signature:

If issued by a legal entity, the form must be signed by authorized representative(s) and be accompanied by a registration certificate or, concerning foreign legal entities, corresponding documents evidencing the authorized representative(s) of the shareholder.

The form, and a copy of the registration certificate or corresponding documents (if applicable) shall be sent to InDex Pharmaceuticals Holding AB, Berzelius väg 13, SE-171 65 Solna, Sweden or to info@indexpharma.com.

In Schedule 1, the votes shall be set forth. The shareholder may not vote in any other way than by marking one of the available alternatives. If the shareholder has not marked an alternative on a particular issue, the shareholder is considered to have abstained from voting on that issue. For complete proposals for resolutions, please refer to the notice of the general meeting and the complete proposals on www.indexpharma.com.

Since the meeting will be held without physical presence of shareholders, proxies and/or external parties and the shareholders have only the opportunity to vote by mail prior to the annual general meeting, the shareholder has the opportunity to choose that decisions in one or several of the matters in Schedule 1 shall be postponed to a continued general meeting. In such case, the shareholder shall specify this in accordance with the instructions in Schedule 1. A continued general meeting will not be held solely through postal voting.

Should you have any questions, please contact the company via e-mail address info@indexpharma.com or phone number +46 8 122 038 50.

Please note that submitting this form will be regarded as giving notice of your attendance at the meeting. A prerequisite for a mail vote to be taken into account is that the shareholder who has cast the vote is included in the share register on the record date for the meeting, which is on the 23 May 2022. Shareholders with nominee-registered shares must temporarily reregister their shares in their own name with Euroclear Sweden AB. Accordingly, shareholders must inform their trustee of this request in ample time prior to 25 May 2022, at which the reregistration must be completed. The mail voting form must reach the company on 31 May 2022 at the latest.

This mail voting form may be revoked by written notice via e-mail to info@indexpharma.com, no later than 31 May 2022.

Schedule 1 follow on the next page

Schedule 1 to the Mail Voting Form

Shareholder

Name of the shareholder:	Personal identification number or corporate registration number:
--------------------------	--

The votes below are cast by the shareholder above, for the resolutions at the annual general meeting on 1 June 2022 in InDex Pharmaceuticals Holding AB, reg. no. 559067-6820, according to the proposed agenda set forth in the notice to attend the general meeting. The content of each proposal, if applicable, can be found in the complete proposals published on the company's website and otherwise in the notice.

1. Opening of the meeting and election of chairman of the meeting <i>Election of Marcus Nivinger as chairman of the meeting or if he is unable to attend the meeting, any other person proposed by the board of directors</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
2. Preparation and approval of the voting list	Yes <input type="checkbox"/>	No <input type="checkbox"/>
3. Approval of the agenda	Yes <input type="checkbox"/>	No <input type="checkbox"/>
4. Election of at least one person who shall approve the minutes of the meeting <i>Karl Tobieson, Linc AB, or in the event he is prevented from doing so, the person the board of directors appoints instead</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
5. Determination of whether the meeting has been duly convened	Yes <input type="checkbox"/>	No <input type="checkbox"/>
7a. Resolution in respect of adoption of the profit and loss statement and the balance sheet as well as of the consolidated profit and loss statement and the consolidated profit and loss statement and balance sheet for the group	Yes <input type="checkbox"/>	No <input type="checkbox"/>
7b. Resolution in respect of the company's profits or losses according to the adopted balance sheet	Yes <input type="checkbox"/>	No <input type="checkbox"/>
7c. Resolution in respect of the members of the board of directors' and the CEO's discharge from liability <i>Wenche Rolfsen (chairman of the board)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Marlene Forsell (board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Uli Hacksell (board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Lennart Hansson (board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Peter Zerhouni (CEO)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
8. Determination of the number of members of the board of directors, and if applicable deputy members of the board of directors, as well as of the number of auditors, and if applicable deputy auditors	Yes <input type="checkbox"/>	No <input type="checkbox"/>
9. Determination of the fees payable to the members of the board of directors and the auditor	Yes <input type="checkbox"/>	No <input type="checkbox"/>
10. Election of members of the board of directors and auditor <i>Wenche Rolfsen (as board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Marlene Forsell (as board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Uli Hacksell (as board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Lennart Hansson (as board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Karin Bernadotte af Wisborg (as board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Anna-Kajja Grönblad (as board member)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>Wenche Rolfsen (as chairman of the board)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
<i>PricewaterhouseCoopers AB (PwC) (as auditor)</i>	Yes <input type="checkbox"/>	No <input type="checkbox"/>

Schedule 1 continue on the next page

11. Resolution regarding authorization for the board of directors to increase the share capital	Yes <input type="checkbox"/>	No <input type="checkbox"/>
12. Resolution on implementation of a long term incentive program in the form of employee stock options for senior executives and other key persons in the group including (i) a directed issue of warrants and (ii) approval of transfer (Employee Stock Option Program 2022/2025)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
13. Resolution on implementation of a long-term incentive programme for board members by way of (i) a directed issue of warrants and (ii) approval of transfer of warrants (Warrant programme 2022/2027)	Yes <input type="checkbox"/>	No <input type="checkbox"/>

<p>The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued general meeting (Completed only if the shareholder has such a wish)</p> <p>Item/items (use numbering):</p>
